"Centene's recent stock drop is closely linked to a combination of higher-than-expected medical costs amid challenging trends in the Affordable Care Act (ACA) market and anticipation of the scheduled end to enhanced ACA subsidies at the end of 2025. While shares jumped earlier this week after Centene affirmed its guidance, which was higher than analysts' estimates, it faces an uncertain road ahead."
"Stock performance: Centene's shares fell sharply in early July, reaching their lowest levels in nearly a decade. This plunge was triggered by worse-than-expected financial results, withdrawals of 2025 earnings guidance, and recognition of higher-than-expected medical costs as well as rising morbidity in its ACA and Medicaid populations. ACA subsidies set to end: The enhanced ACA premium subsidies passed under the American Rescue Plan (ARP) and extended under the Inflation Reduction Act (IRA) are scheduled to sunset on Dec. 31."
Centene's stock fell more than 42% over six months after the company withdrew 2025 financial guidance amid troubling developments in its core health insurance business. The company reported higher-than-expected medical costs and rising morbidity in its ACA and Medicaid populations, contributing to a Q2 2025 loss, the first in over a decade. Enhanced ACA premium subsidies enacted under the American Rescue Plan and extended under the Inflation Reduction Act are scheduled to sunset on Dec. 31, 2025, risking reduced support for Marketplace enrollees. The subsidy expiration could shrink the pool of healthier enrollees and create adverse selection, increasing medical costs and compressing margins. Market uncertainty and policy risk pose ongoing headwinds for near-term profitability and investor confidence.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]